Perspectives gained from large-scale thrombolytic comparative trials
View abstract on PubMed
Summary
This summary is machine-generated.Accelerated tissue plasminogen activator (t-PA) with heparin improves outcomes in acute myocardial infarction. Identifying patient subsets and bleeding risks optimizes treatment decisions for better survival and cardiac function.
Area Of Science
- Cardiology
- Clinical Trials
- Pharmacology
Background
- Four large thrombolytic trials (GISSI-2, ISIS-3, GUSTO, INJECT) compared treatments for acute myocardial infarction (AMI).
- Differences in GUSTO results were linked to intravenous heparin and accelerated tissue plasminogen activator (t-PA) regimens.
Purpose Of The Study
- To identify patient subsets benefiting most from accelerated t-PA.
- To develop a profile for patients at risk of intracranial hemorrhage.
- To assess the impact of early coronary artery patency on left ventricular function and survival.
Main Methods
- Analysis of predefined parameters in large patient populations (>1000).
- Angiographic substudy within the GUSTO trial.
- Evaluation of international practice patterns, quality of life, and return to work.
Main Results
- Accelerated t-PA with heparin demonstrated improved outcomes compared to earlier strategies.
- Patient-specific risk profiles for intracranial hemorrhage were identified.
- Early coronary artery patency significantly improved left ventricular function and survival.
Conclusions
- Individualized treatment decisions using patient profiles enhance care for AMI.
- Left ventricular function serves as a valuable surrogate for assessing reperfusion strategies.
- Future research should focus on resource optimization for novel therapy assessment in AMI.